View Older Stories View More Recent Stories

Nov 2, 2016 12:20PM New data from pivotal RA-BEACON study show significant improvement in patient-reported outcomes in rheumatoid arthritis patients treated with baricitinib compared to placebo
Nov 2, 2016 08:00AM Incyte to Present at Upcoming Investor Conference
Nov 1, 2016 07:00AM Incyte Reports 2016 Third-Quarter Financial Results and Updates Key Clinical Programs
Oct 14, 2016 08:30AM Cancer Immunotherapy ETF Celebrates One-Year Anniversary
Oct 14, 2016 08:00AM Incyte to Report Third Quarter Financial Results
Oct 7, 2016 05:40AM Incyte (INCY) Issues Updates on Epacadostat + Keytruda Phase 1; Says Median PFS Not Reached (MRK)
Oct 7, 2016 04:07AM Additional Phase 1 Data from ECHO-202 Reinforce Durability of Response in Patients with Treatment-naive Advanced or Metastatic Melanoma Treated with Epacadostat in Combination with Keytruda® (pembrol
Sep 28, 2016 06:16AM Incyte (INCY) Announces Publication of Updated Phase 1 Data on Epacadostat + Keytruda in Advanced Melanoma (MRK)
Sep 28, 2016 06:11AM Updated Phase 1 Data Reinforce the Clinical Profile of Epacadostat in Combination with Keytruda® (Pembrolizumab)
Sep 27, 2016 07:46AM Incyte (INCY) Says Jakafi Recommend by NCCN for Myelofibrosis
Sep 27, 2016 07:45AM NCCN Guidelines® Recommend Jakafi® (ruxolitinib) for the Treatment of Myelofibrosis
Sep 8, 2016 09:00AM Incyte Supports Those Affected by Rare Blood Cancers on MPN Awareness Day and Throughout Blood Cancer Awareness Month
Aug 30, 2016 08:00AM Incyte to Present at Upcoming Investor Conferences
Aug 25, 2016 07:30AM Forbes Magazine Names Incyte to its List of World’s Most Innovative Companies for Second Consecutive Year
Aug 9, 2016 07:00AM Incyte Reports 2016 Second-Quarter Financial Results and Updates Key Clinical Programs
Jul 19, 2016 07:35AM Updated Data for Epacadostat, Incyte’s Selective IDO1 Inhibitor, Accepted for Presentation at the ESMO Annual Congress 2016
Jul 14, 2016 08:00AM Incyte to Report Second Quarter Financial Results
Jun 23, 2016 07:30AM Incyte's (INCY) Jakafi Receives FDA Breakthrough Therapy Designation in Acute GVHD
Jun 23, 2016 07:30AM FDA Grants Breakthrough Therapy Designation for Incyte’s Ruxolitinib (Jakafi®) in Acute Graft-Versus-Host Disease (GVHD)
Jun 22, 2016 04:36PM Incyte (INCY) Treats First Patient in ECHO-301 Combo Phase 3 (MRK)
Jun 22, 2016 04:35PM Incyte Announces First Patient Treated in ECHO-301 Phase 3 Study
Jun 14, 2016 11:25AM Goldman M&A Basket in Focus After Predicting LinkedIn (LNKD); (TWTR) (BLUE) (TRIP), Others Added
Jun 10, 2016 02:35AM New Phase 3 Data Show Jakafi® (ruxolitinib) is Superior to Best Available Therapy in Patients with Polycythemia Vera (PV)
Jun 9, 2016 06:48AM Eli Lilly & Co. (LLY), Incyte (INCY) Report Baricitinib Superiority to Placebo in Inhibiting RA-Related Joint Damage
Jun 9, 2016 06:47AM Eli Lilly & Co. (LLY), Incyte (INCY) Announce Significant Data from Two Baricitinib Phase 3s in RA
Jun 9, 2016 06:45AM Patient-reported outcomes across phase 3 studies of baricitinib demonstrate statistically significant improvements in physical function and quality of life symptoms in patients with rheumatoid arthrit
Jun 9, 2016 06:45AM Baricitinib significantly reduces joint damage progression in rheumatoid arthritis in patients who do not respond to conventional DMARDs
Jun 6, 2016 07:39AM Incyte (INCY) Announces Positive OS Results from Jakafi Phase 3 in Certain Myelofibrosis
Jun 6, 2016 07:35AM Five-year Results from Phase 3 Study of Jakafi® (ruxolitinib) Show Sustained Overall Survival Benefit in Patients with Myelofibrosis (MF)
Jun 2, 2016 07:36AM ARIAD Pharma (ARIA) Announces Completion of European Ops Sale to Incyte (INCY)
Jun 1, 2016 07:35AM Incyte and Moffitt Cancer Center Establish Multi-Year Oncology Research Alliance
May 31, 2016 04:35PM Incyte Announces the Launch of the Incyte Charitable Giving Foundation
May 19, 2016 08:31AM Incyte Highlights Jakafi® (ruxolitinib) and Capmatinib Abstracts to be Presented at the 2016 ASCO and EHA Annual Meetings
May 18, 2016 08:00AM Incyte to Present at Upcoming Investor Conferences
May 9, 2016 07:55AM Incyte First Quarter Financial Results Conference Call and Webcast
May 9, 2016 07:03AM Incyte (INCY) to Acquire ARIAD's (ARIA) European Operations; Will in-License Iclusig
May 9, 2016 07:00AM Incyte Reports 2016 First-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
May 9, 2016 07:00AM Incyte and ARIAD Announce Agreement for Incyte to Acquire ARIAD’s European Operations and In-license Iclusig® (ponatinib) in Europe
Apr 28, 2016 08:00AM Incyte to Present at Upcoming Investor Conferences
Apr 15, 2016 04:35PM Incyte Investor Event at AACR 2016 to Highlight Innovative and Diversified Research and Development Portfolio
Apr 14, 2016 08:00AM Incyte to Report First Quarter Financial Results
Apr 6, 2016 07:31AM Incyte (INCY) Acquires Jakafi Commercialization, Development Rights from Lilly (LLY)
Apr 6, 2016 07:30AM Incyte Acquires Rights from Lilly to Develop and Commercialize Ruxolitinib (Jakafi®) for the Treatment of Patients with Graft-Versus-Host Disease (GVHD)
Feb 11, 2016 09:24AM Pre-Open Stock Movers 02/11: (NTWK) (EXPE) (TRIP) (CSCO) Higher; (FLO) (LPSN) (INCY) Lower (more...)
Jan 21, 2016 09:28AM Pre-Open Stock Movers 01/21: (ZFGN) (XLNX) (FEYE) Higher; (OGXI) (ALKS) (SLM) Lower (more...)
Oct 13, 2015 07:30AM Incyte and Merck Expand Clinical Collaboration to Include Phase 3 Study Investigating the Combination of Epacadostat with Keytruda® (pembrolizumab) as First-line Treatment for Advanced Melanoma
View More Recent Stories View Older Stories